Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the period from January 1, 2023 to December 31, 2023. For the period, Company expects Net loss attributable to Shareholders of the listed company of RMB 924.0 million to RMB 647.0 million against Earnings of RMB 727.1 million a year ago. Net loss after non-recurring profit or loss of RMB 921.0 million to RMB 644.0 million against Earnings of RMB 748.2 million a year ago.

Basic loss per share of RMB 0.6297 per share to RMB 0.4409 per share against Earnings of RMB 0.4955 per share a year ago.